Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580708 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Clovis Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02580708: Clinical Trial Phase 1 study, sponsored by Clovis Oncology.
NCT02580708 is a Phase 1 study that was terminated before completion, run by Clovis Oncology. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02580708, a Phase 1 study, was terminated before completion, sponsored by Clovis Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
Primary Outcome
Treatment emergent adverse events (AEs), laboratory abnormalities and ECG abnormalities in EGFR-mutant NSCLC patients given oral rociletinib in combination with oral trametinib; defining in Phase 1 the recommended combination dose for further evaluation in Phase 2
Interventions
- DRUG Trametinib
- DRUG Rociletinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2016-06-27 |
| Phase | Phase 1 |
Why NCT02580708 stopped before completion
NCT02580708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Trametinib is the first listed.
NCT02580708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02580708 about?
NCT02580708 is a clinical study titled "Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer". The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
What is the current status of trial NCT02580708?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-09-30. Estimated completion is 2016-06-27.
What interventions are being tested in trial NCT02580708?
The interventions under investigation include: Trametinib (DRUG), Rociletinib (DRUG).
Who is sponsoring clinical trial NCT02580708?
This trial is sponsored by Clovis Oncology, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02580708's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI